
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx is performing well financially with consistent revenues and a strong cash position, allowing for the development and potential FDA approval of their promising drugs Ibsrela and Xphozah. Their focus on expanding into other potential indications and developing new drugs shows a long-term growth strategy. Additionally, the positive clinical trial results and significant market opportunity add to the overall positive outlook for the company's stock.
Bears say
Ardelyx is facing several potential barriers to success, including a highly competitive market for its Ibsrela and Xphozah products, challenges in patient enrollment for clinical trials, and the potential for pull-forward effects due to the rapid pace of site activation. While the company has maintained its revenue guidance for FY26, there could be limitations to its growth potential and the potential for upside may be limited due to the crossover of symptoms between CIC and IBS-C, as well as the challenging nature of IBS-C as a condition to treat. Additionally, the company's increase in combined R&D and SG&A expenses may impact its overall financial performance and ability to generate profit.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares